Patrys Limited (ASX:PAB)

Market Cap	20.00M +289.0%
Revenue (ttm)	100.38K -93.1%
Net Income	-4.51M
EPS	-0.02
Shares Out	666.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	865,817
Average Volume	966,425
Open	0.0310
Previous Close	0.0310
Day's Range	0.0300 - 0.0310
52-Week Range	0.0120 - 0.0490
Beta	0.99
RSI	50.73
Earnings Date	May 27, 2026

About Patrys

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is base...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 10
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PAB

Financial Performance

In fiscal year 2025, Patrys's revenue was 828,540, a decrease of -40.57% compared to the previous year's 1.39 million. Losses were -3.01 million, -14.86% less than in 2024.